LEVEL OF AWARENESS OF REPUBLIC BULGARIA’S POPULATION FOR TREATMENT OF ISCHEMIC STROKE VIA THROMBOLYSIS

Greta KOLEVA
Irinka HRISTOVA
Despina GEORGIEVA
Daniela DRAGANOVA
Ivanichka SERBEZOVA

1 Assist, Ruse, Riga str. 38, University of Ruse, Pedagogy Department
2 Assist, Ruse, Riga str. 38, University of Ruse, Pedagogy Department
3 Assist Prof, Ruse, Riga str. 38, University of Ruse, Pedagogy Department
4 Assist - Ruse, Riga str. 38, University of Ruse, Pedagogy Department
5 Professor, PhD, Ruse, Riga str. 38, University of Ruse, Pedagogy Department

Abstract: The stroke is a socially significant disease that is characterized with high levels of morbidity and mortality, causing severe disability worldwide. It is the second most significant cause of death among the people in the western world, falling back only to the heart diseases and preceding the cancer, as it causes 10% of the mortal cases in the world. Since 2009 the Bulgarian association of neurosonology and cerebral hemodynamics(BANCH) organizes different initiatives of training doctors to conduct a thrombolytic treatment to acute ischemic stroke(AIS). The intravenous thrombolysis has not been established as a leading differential treatment of AIS in Bulgaria, and the thrombolytic therapy is still not well developed in Bulgaria. The support of national and local institutions is crucial for insuring and guarantee for a proper stroke treatment. Efforts are necessary for adequate financing of the health facilities, as well as professional preparation of the human resource, and training the population via creating an integrated national strategy for its application and control, which can underline as a state politics in healthcare at optimal usage of public-private partnership.

Keywords: ischemic stroke, thrombolysis, Actilyse®, stroke unit

Introduction: The stroke is an acute disturbance of the cerebral blood circulation, as a result of which, the cerebral functions are impaired to a different degree of damage. The definition of stroke, offered by the World health organization(WHO) in 1970 [19], is “a neurological deficiency with a cerebrovascular origin, running for over 24 hours, or interrupted due to death within those 24 hours”. This definition shows the reversibility of the tissue damage, as the 24-hour frame is provisionally selected. It is introduced to distinguish the stroke from a TIA, which runs with very similar symptoms, but fades within 24 hours [16]. With the opportunity for an early therapy, which reduces the stroke's acuteness, many prefer to use the term cerebral attack and an acute ischemic cerebrovascular syndrome(similar to heart attack and acute coronary syndrome) [19].

The stroke comprises of two groups: ischemic and haemorrhagic [15]. The ischemic stroke is the one which is caused by a disturbance of the blood supply, whereas the haemorrhagic ones are a result of a broken blood vessel, or abnormal vessel structure. About 87% of the strokes are caused by ischemia. Some haemorrhagic strokes are developed in ischemic areas(“a haemorrhagic transformation”). It is unknown how much haemorrhagic strokes start at the beginning as ischemic ones [16]. Due to ischemic stroke, the blood supply to some part of the brain is limited, which results in disfunction or a permanent damage of this part of the brain. There are four known reasons for this to happen:
1. Thrombosis (a local clot blockage of a blood vessel);
2. Embolism (a clot blockage formed somewhere on the body) [16]
3. Systemic hypoperfusion (an overall reduction of the blood flow, for example in shock) [24];
4. Thrombosis of cerebral venous sinuses (vessels carrying the blood from the brain to the jugular vein) [25].

Strokes without any obvious explanation and of unknown descent are considered cryptogenic. Such are about 30-40% of all ischemic strokes [16, 18]. But, it will soon probably become the main cause of death in the world [20]. The risk of stroke increases after the age of 30, and its etiology changes as age progresses [17]. Advanced age is one of the most significant risk factors for a stroke to arise. 95% of the cases occur in people over 45 years old, and 2/3 occur in those over 65 years old [17, 23]. The risk for a patient to die due to acquired stroke increases as
stroke for the first six months of 2014, 25,600 of
and analysis, 26,654 people in our country got a
According to the National Centre for public health
Table 1.
Table 1. Number of patients by age that
got IS for the first six months of 2014.

<table>
<thead>
<tr>
<th>Men</th>
<th>Age</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>under 35 years</td>
<td>23</td>
</tr>
<tr>
<td>1014</td>
<td>from 35 to 55 years</td>
<td>713</td>
</tr>
<tr>
<td>10 196</td>
<td>over 55 years</td>
<td>11 809</td>
</tr>
</tbody>
</table>

The number of Bulgarians who got a stroke in
daughter age (under 55 years), is 1875; men
well. Still, it is possible for a stroke to occur at any
age, even during childhood. The main risk factors
for the stroke are the family history, as well as
lifestyle. Contributive factors are hypertension,
atherosclerosis, atrial fibrillation, a myocardial
infarction in the past, diabetes, hyperlipidaemia,alcohol and drug abuse, etc.
Among the people who went through a stroke for
the first time, the higher levels of von Vilebrand
factor stand out (it's a plasma protein having to do
with coagulation) [14].
A past stroke is a highly great risk factor for
acquiring a new one. A combined effect of several
of the aforementioned risk factors, increases the
risk of stroke significantly. According to the World
health organization(WHO), 15 million people get ill
of stroke annually around the world, 5 million of
them die and 5 million remain permanently
disabled. The number of stroke-ill people in
Europe is expected to increase by 30% between
2000-2025 [27]. The mortality in Central and
Eastern Europe is higher in comparison to that of
North, South and Western Europe. 57% of the
expenses for cardiovascular diseases in the EU
go for healthcare, 21% are due to loss of labour
efficiency, and 22% go for care to survivors [12].
In late 2008 Bulgaria has the highest rate of
mortality (14.5 to 1000 people), and is in the top
places in mortality by strokes - every fifth or sixth
man dies from stroke in the country, and every
fourth or fifth woman, whereas in Europe- every
tenth man and seventh woman [12,28]. Moreover
the sick rate and mortality from strokes is much
higher among those who live in the villages [21].
The disability for those who had survived a stroke
extends to 50-75%.
According to the National Centre for public health
and analysis, 26,654 people in our country got a
stroke for the first six months of 2014, 25,600 of
which have been hospitalized, 1054 of them have
refused hospitalization and 2904 respectively of
all have died, and 932 of the unhospitalized as
well. 23,780 patients suffer from an ischemic
stroke(IS). The gender distribution is shown on
Table 1.

The differential thrombolytic treatment of AIS in
Bulgaria with applying a recombinant tissue
plasminogen activator(rt-PA) Actilyse® is
introduced in 2005- the first thrombolyis is made
in Plovdiv [1]. Treatment with thrombolysis in
Europe and the USA is applied since 2002 until
now. In Europe and the US thrombolysis is
administered since 2002. Staykov quoting other
sources, states as a key objective of both - the
intravenous and intra-arterial thrombolysis
restoration of blood flow through arteries with
obturation and prevent irreversible disturbance in
the area of so-called penumbra: restoring
circulation and normalization of metabolism in
neighboring infarct functionally impaired tissue [4]
by “melting” the resultant clot. Penumbra - from
the Latin "Paene" (almost) and "umbra" (shadow)
or ischemic penumbra. This area can be restored
by an early intervention to improve blood
circulation.
By the end of 2009 in Bulgaria were made about
150 intravenous thrombolysis and several intra-
arterial, which is significantly below the expected
minimum of 1% and varies from 0.04% (2006) to
0.1% per year (2009) [1]. Treatment is regulated
by the clinical pathway № 2 NHIF and is
conducted in a neurology clinic / ward with
intensive care unit with the possibility of
respiratory support if needed, or in SICU
according to current medical standard "Neurology"
By 2011, in Bulgaria intravenous administration of
recombinant tissue plasminogen activator (rtPA -
Alteplase, Actilyse) applies only to the first three
hours of the occurrence of ischemic stroke in
persons 18 to 75 years of age (for Europe 80
years). Although the study ECASS III (European
Cooperative Acute Stroke Study III) showed good
safety and efficacy of the application of rt-PA
between 3-4.5 hours of the onset of symptoms
[22]. This time limit may be raised to 4.5-6 hours
using intra-arterial thrombolysis and / or
endovascular recanalization (mechanical
thrombus extraction or stenting).
In other studies the authors compared the effects
after stroke, and the risk of bleeding in patients
treated with rt-PA to the third hour, with those in
patients with intravenous thrombolysis
administered between three and six hours. The
conclusion is that for the certain group of patients
the therapeutic window may be extended up to six
hours of early vascular accident.
Similar results were obtained from a number of
studies - clinically randomized and placebo-
controlled, multi-centered clinical studies indicate
that administration of intravenous thrombolysis after the third hour, is associated with a lower incidence of intracerebral bleeding and a high percentage of recovery [8]. Experts in the field believe that there is sufficient evidence that application of Actilyse between 0 and 4.5 hours, after the onset of symptoms of acute ischemic stroke can be considered economically viable therapy, as this reduces the likelihood of disability, death or dependency on the care of others. In November 2011 the European Medicines Agency (EMA) has approved changes in the indications of Actilyse via prolonging the application of this drug from three to 4.5 hours, after the onset of clinical symptoms in patients with acute ischemic stroke. Permit outside the three-hour time period, is based on the results of the European study ECASS 3, which is defined as a milestone in the venous thrombolysis with rt-PA. ECASS 3 was a randomized, double-blind, placebo-controlled study, which for the first time demonstrated that thrombolysis with Alteplase can increase favorable outcome with minimal or no disability after an acute ischemic stroke, when treatment is started in time window of 3 to 4.5 hours after symptom onset [13].

In Bulgaria extending the time window for administration of Alteplase to 4.5 hours was approved under a national procedure since April 2011 [9]. There are a number of contraindications, making procedures inapplicable in a relatively large number of patients with ischemic stroke, reached in a timely manner to the health facility: NIHSS neurological assessment by over 22 points, intracranial hemorrhage, increased bleeding hazard (in systolic blood pressure over 185 and diastolic 110 mmHg); a history of intracranial hemorrhage, patients anticoagulated with INR> / = 1.5, prothrombin time under 60%, taking heparin and extended aPT, platelets below 100,000, brain injury in the past, or ischemic stroke over the last three months, intracranial neoplasia, AB-malformation, aneurysms, hemorrhagic retinopathy / eg diabetic / severe uncontrolled hypertension, varicosis of esophagus documented gastric ulcer during the last 3 months; severe neonatal liver disease / cirrhosis, hepatitis / or GI bleeding, or bleeding from the urinary tract during the last 21 days , arterial puncture in the last seven days; severe CNS trauma in the last three months, major surgery or serious injury in the last 14 days); blood glucose below 2.5 mmol / L; seizures; myocardial infarction in the past three months, endocarditis, pericarditis, acute pancreatitis [10].

Among other reasons that determine the limited use of intravenous thrombolysis in cases of acute ischemic stroke (AIS) in Bulgaria may include: lack of Specialized units (stroke units) and trained multidisciplinary teams for its implementation; a limited number of hospitals eligible for equipment and human resources, that do not cover the entire territory of the country; the absence of a good relations between the teams of the EMS and the hospital units performing the procedure; lack of sufficient information to the public, outpatient and emergency assistance for this therapy; lack of a national registry of diseased with AIS; and a national program for the prevention of strokes. There are financial constraints and organizational problems [2]. From Andonova's and others' research for the period 2007-2009 in "St.. Marina " University hospital - Varna, it is clear that the hospitalized patients with ischemic stroke (IS) are 2935, but only 20 of them have been conducted with a thrombolytic therapy. After analyzing the technological time to implement all procedures and tests covered by the Protocol, in 97 patients is found that time ranging from 1.46 to 2.23 hours.

The low frequency of thrombolysis in patients with IS is explained by the delayed hospitalization and delayed lab results - after the 3rd hour of stroke onset. It is also because of poor collaboration between teams of EMS on the one hand, and the teams of a ER and the multidisciplinary team on the other hand. The absence of a national registry of patients undergone thrombolytic therapy, takes the opportunity to analyze nationwide effect of the therapy on neurological deficit, estimated to NIHSS-scale [6]. Prof. Nedeltchev head of neurology clinic in Triemli Hospital in Zurich, shared the measures taken in Switzerland in 2010 in connection with the early recognition of the symptoms of AIS. Repeatedly in prime time television broadcast video information, is explained what could be the symptoms, and when they are recognized, that an important contact with person from the emergency services should be done, in order to identify and confirm potential patient with stroke. The 112 operator can ask a few questions in high sensitivity in order within the time window, the patient to be transferred in a specialized center. Several specialized university hospitals in Switzerland thrombolize 20-25% of patients with ischemic stroke. These centers admit patients especially for thrombolytic procedures. Teams working in there are specially selected, and work on all known methods for thrombolysis, namely intravenous, intra-arterial thrombolysis and combined [7].
In order to determine the awareness of the population about the disease Ischemic stroke, its signs and ways of treatment was conducted survey. For the purpose of the study have been designed questionnaire consisting of seven questions from a closed and one from open type. 322 adults from the town of Rousse - men and women of 18-85 years with different social status and profession had been questioned. The research period is from 1st to 15th May 2015. Statistical data processing is carried out with the program SPSS 16.0. The results show low levels of awareness about the nature of Ischemic stroke, the reasons for its occurrence and opportunities for therapy. The survey results are presented in tabular form.

Table 2. Awareness of Ischemic Stroke

<table>
<thead>
<tr>
<th>Do you know what Ischemic stroke is?</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>158</td>
<td>49,1 %</td>
</tr>
<tr>
<td>No</td>
<td>136</td>
<td>42,2 %</td>
</tr>
<tr>
<td>I have no idea</td>
<td>28</td>
<td>8,7 %</td>
</tr>
</tbody>
</table>

Only 49.1% of respondents know the signs of IS, which logically leads to the result shown in Table 3.

Table 3. Awareness of the signs of IS

<table>
<thead>
<tr>
<th>Do you know the signs of the illness?</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>136</td>
<td>42,2 %</td>
</tr>
<tr>
<td>No</td>
<td>182</td>
<td>56,5 %</td>
</tr>
<tr>
<td>No reply</td>
<td>4</td>
<td>1,2 %</td>
</tr>
</tbody>
</table>

When asked to point out some signs of stroke occurring, 230 / 71.4% / patients did not reply, and the remaining 28.6%, gave some of the following answers: loss of consciousness, paralysis, loss of speech, eye haemorrhage, dizziness, inadequacy, rigidity, paralysis of the body, high blood pressure, brain fatigue, numbness of limbs, numbness of left arm combined with pain in the right leg, confusion, rambling speech, spontaneous release of urine and feces, when there is no blood clotting in the head, tongue twisting and others.

Table 4. Origin of information about the disease.

<table>
<thead>
<tr>
<th>Where do you get information about the disease?</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>From GP</td>
<td>202</td>
<td>62,7 %</td>
</tr>
<tr>
<td>Healthcare workers</td>
<td>58</td>
<td>17,4 %</td>
</tr>
<tr>
<td>From internet</td>
<td>46</td>
<td>14,3 %</td>
</tr>
<tr>
<td>From friends and relatives</td>
<td>4</td>
<td>1,2 %</td>
</tr>
<tr>
<td>From mass media</td>
<td>2</td>
<td>0,6 %</td>
</tr>
<tr>
<td>No comment</td>
<td>12</td>
<td>3,7 %</td>
</tr>
</tbody>
</table>

The main source of information, as shown in Table 4 is the GP. The conclusions that can be drawn is that the information on the IS is insufficient and unclear to people. The results presented in Table 5 confirm the importance of the GP for responding to respondents’ expectations to obtain information about the disease.

Table 5. Expected information

<table>
<thead>
<tr>
<th>Whom / where from do you expect to receive information about the disease?</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visiting the GP</td>
<td>202</td>
<td>62,7 %</td>
</tr>
<tr>
<td>Information leaflets</td>
<td>56</td>
<td>18,1 %</td>
</tr>
<tr>
<td>From mass media</td>
<td>64</td>
<td>19,2 %</td>
</tr>
</tbody>
</table>

Table 6. Expected aid

<table>
<thead>
<tr>
<th>When first signs of IS start to manifest, where will you seek help from?</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP</td>
<td>62</td>
<td>19,3 %</td>
</tr>
<tr>
<td>Number 112</td>
<td>240</td>
<td>74,5 %</td>
</tr>
<tr>
<td>Family and relatives</td>
<td>14</td>
<td>4,3 %</td>
</tr>
<tr>
<td>I will wait them to go away</td>
<td>6</td>
<td>1,9 %</td>
</tr>
</tbody>
</table>

Most of the respondents 74.5%, know that at the first sign of the disease is necessary to seek urgent help. 20% of respondents believe that they know modern methods of treatment of IS, and 80% did...
not know the methods of treatment. These answers logically lead to the result in Table 7.

**Table 7.** Thrombolytic therapy

<table>
<thead>
<tr>
<th>What is thrombolytic therapy?</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medicated method aimed at &quot;melting&quot; of the formed thrombus</td>
<td>166</td>
<td>51,6 %</td>
</tr>
<tr>
<td>Invasive removal of the thrombus</td>
<td>52</td>
<td>16,1 %</td>
</tr>
<tr>
<td>Introduction of drugs stimulating brain circulation</td>
<td>78</td>
<td>24,2 %</td>
</tr>
<tr>
<td>No comment</td>
<td>26</td>
<td>8,1 %</td>
</tr>
</tbody>
</table>

Detected is lack of awareness of the population about the time range for thrombolytic therapy. / Table 8 / Of all people questioned only 51.6% had pointed out up to 4,5h.

**Table 8.** Time range for thrombolytic therapy

<table>
<thead>
<tr>
<th>What time span is required for thrombolytic therapy in IS?</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Up to 4,5 h</td>
<td>180</td>
<td>51,6 %</td>
</tr>
<tr>
<td>Up to 6 h</td>
<td>94</td>
<td>16,1 %</td>
</tr>
<tr>
<td>Up to 12 h</td>
<td>34</td>
<td>24,2 %</td>
</tr>
<tr>
<td>No comment</td>
<td>14</td>
<td>8,1 %</td>
</tr>
</tbody>
</table>

Respondents fall into the following age groups / Table 9 /

**Table 9.** Age

<table>
<thead>
<tr>
<th>Your age refers to the group:</th>
<th>Number of people answered</th>
<th>Number of people answered as %</th>
</tr>
</thead>
<tbody>
<tr>
<td>18 – 24 years.</td>
<td>118</td>
<td>36,6 %</td>
</tr>
<tr>
<td>25 – 34 y.</td>
<td>24</td>
<td>7,5 %</td>
</tr>
<tr>
<td>35 – 44 y.</td>
<td>20</td>
<td>6,2 %</td>
</tr>
<tr>
<td>45 – 54 y.</td>
<td>28</td>
<td>8,7 %</td>
</tr>
<tr>
<td>55 – 64 y.</td>
<td>60</td>
<td>16,6 %</td>
</tr>
<tr>
<td>65 – 74 y.</td>
<td>30</td>
<td>9,3 %</td>
</tr>
<tr>
<td>75 – 84 y.</td>
<td>40</td>
<td>12,4 %</td>
</tr>
<tr>
<td>over 85 years.</td>
<td>2</td>
<td>0,6 %</td>
</tr>
</tbody>
</table>

Of special interest is the comparison of the relationship between age and awareness of patients, about use of modern methods for the treatment of IS, which we found through cross table / Table 10/.

**Table 10.** Knowledge of modern methods by age

<table>
<thead>
<tr>
<th>Knowledge of modern methods</th>
<th>18 -</th>
<th>25 -</th>
<th>35 -</th>
<th>45-54</th>
<th>55-64</th>
<th>65-74</th>
<th>over 75</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numb. of respon.</td>
<td>32</td>
<td>4</td>
<td>4</td>
<td>6</td>
<td>12</td>
<td>4</td>
<td>2</td>
<td>64</td>
</tr>
<tr>
<td>% of replied &quot;yes&quot;</td>
<td>50</td>
<td>6</td>
<td>2</td>
<td>6</td>
<td>9</td>
<td>4</td>
<td>18</td>
<td>62</td>
</tr>
<tr>
<td>% For age</td>
<td>27</td>
<td>6</td>
<td>7</td>
<td>20</td>
<td>21</td>
<td>4</td>
<td>20</td>
<td>13</td>
</tr>
<tr>
<td>% Of all respon.</td>
<td>10</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>9</td>
<td>3</td>
<td>1</td>
<td>12</td>
</tr>
<tr>
<td>Numb. of respon.</td>
<td>84</td>
<td>20</td>
<td>16</td>
<td>22</td>
<td>48</td>
<td>26</td>
<td>40</td>
<td>256</td>
</tr>
<tr>
<td>% of answered &quot;yes&quot;</td>
<td>32</td>
<td>8</td>
<td>2</td>
<td>8</td>
<td>6</td>
<td>8</td>
<td>18</td>
<td>15</td>
</tr>
<tr>
<td>% For age</td>
<td>72</td>
<td>.4</td>
<td>3</td>
<td>80</td>
<td>.0</td>
<td>78</td>
<td>80</td>
<td>86</td>
</tr>
<tr>
<td>% Of all respondents</td>
<td>26</td>
<td>6</td>
<td>2</td>
<td>0</td>
<td>6</td>
<td>9</td>
<td>15</td>
<td>8</td>
</tr>
<tr>
<td>Count</td>
<td>11</td>
<td>6</td>
<td>24</td>
<td>20</td>
<td>28</td>
<td>60</td>
<td>30</td>
<td>42</td>
</tr>
<tr>
<td>% within knowledge of modern methods</td>
<td>36</td>
<td>.2</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td>8</td>
<td>18</td>
<td>9</td>
</tr>
<tr>
<td>% of Tota l</td>
<td>18</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>% within age</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>% of Tota l</td>
<td>36</td>
<td>.2</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td>8</td>
<td>18</td>
<td>9</td>
</tr>
</tbody>
</table>

The conclusions that can be drawn from the research team are limited to:

1. The detected low level of awareness of the population leads to a serious risk of delay of treatment the symptoms of IS and inability to implement effective methods of treatment.

2. Due to the inaccuracy in the presentation of the symptoms when calling at tel. 112, the risk of improper administration of medication increases.

In terms of public awareness is needed to provide accurate and clear specific information.
Another important point is the training of the population in the fastest presenting of prominent symptoms when calling at tel: 112. Unlike European countries, in Bulgaria the role of the nurse in prevention and disease prevention is not regulated. The important role of health care professionals in providing information for socially significant diseases and training of the population has not been established from this research.

CONCLUSIONS
Thrombolytic therapy is not yet sufficiently developed in Bulgaria. Supporting national and local health institutions is crucial to ensure and provide adequate treatment for stroke. Efforts are needed for adequate funding for health care facilities, training of human resources and public education through the creation of a unified national strategy for its implementation and control, which is to form a state policy in health care with optimal use of public-private partnership.

In some European countries like Germany and Austria, there is a network of specialized centres for treating strokes, with strict organization of how to react in case of an IS - immediate calling on 112, an arrival of an Emergency team, an immediate notification of the hospital and the specialized team that's taking the case, and transporting the patient to the so-called stroke unit. About 3% of the patients suffering from IS in Europe are being thrombolized. This percentage in our country is much lower. The information is insufficient among the medical community as well, especially among the GP, the outpatient care and first aid teams. Scientific and practical information concerning the problem, can be found mainly in specialized neurological editions which are spread thoroughly among neurologists [2]. Health care professionals involved in primary care could participate actively in prevention, information and training the patients on disease symptoms and regulated activities after signs of stroke. Actively and adequately tracking the patients of the target group will lead to early detection and even prevention of brain incidents. A programme for targeted surveillance of patients with IS who underwent thrombolytic therapy in order to monitor these patients in the long term is needed. It is the introduction of uniform protocols with highly sensitive anchoring points for quick orientation of employees in emergency aid. Good coordination between the emergency team and the multidisciplinary team will help to reduce the loss of time after admitting the patient in a hospital and rapid organization of instrumental and clinical - laboratory and within 60 minutes to start thrombolysis as it is accepted in the European recommendations. In the future, the creation of a large network of specialized clinics for treatment of stroke with thrombolysis is recommended, like the laboratories for the treatment of myocardial infarction because only the treatment in the first hours of the incident would avoid adverse consequences for the patient and society the loss of functional independence and ability to work. The enormous economic burden of high costs for these patients can be saved [5]. Patients and their families should be able to adequately respond to suspected stroke occurring, indicate the exact time of its occurrence and its exact description. Media must actively participate in the promotion of symptoms and response pattern of the population in case of stroke, similarly to the European and world experience.

BIBLIOGRAPHY
[7] Todorova E., Thrombolysis is the most effective treatment for ischemic stroke, doctors should not be afraid to apply it, www.zdrave.net, 24.4.2010 http://www.zdrave.net/Portal/WeekGuest/Default.aspx?evntid=EG9Zxnmlbz0%3D

DOI: 10.21279/1454-864X-16-I1-072
© 2015. This work is licensed under the Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.


